United States Prostate Cancer Testing Market By Biomarker Type (Pre-Biopsy/Post-Negative Biopsy Testing, Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA), Post-Biopsy Tissue Testing), By Application (Diagnostics Biomarkers, Prognostics Biomarkers), By End User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals and Clinics, Ambulatory Surgical Center (ASCs), and Othe
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationUnited States Prostate Cancer Testing Market By Biomarker Type (Pre-Biopsy/Post-Negative Biopsy Testing, Initial Evaluation: Prostate-Specific Antigen (Total PSA, Free PSA), Post-Biopsy Tissue Testing), By Application (Diagnostics Biomarkers, Prognostics Biomarkers), By End User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals and Clinics, Ambulatory Surgical Center (ASCs), and Othe
According to Global Cancer Observatory, in 2020, around
According to Statista, the United States leads among all countries across the globe in terms of spending on research and development, with expenditure exceeding around USD679.4 billion.
Rising prevalence of prostate cancer
For instance, in the United States, it was predicted that about 268,490 new cases of prostate cancer were reported in 2022, up from 192,280 new cases in 2009. Moreover, it was estimated that in 2022 around 34,500 men would die of prostate cancer in the U.S.
Growing Geriatric Population
Government Initiatives related to Prostate Cancer
Technological Development
The techniques like prostate-specific antigen (PSA) testing which have developed over the years that confirm the tumor progression and proliferation have created new prospects for the growth of prostate cancer testing over the years.
Recent Developments
According to the Journal of the National Cancer Institute, in September 2022, a company namely Veracyte, Inc. announced the publishing of data to demonstrate that the company’s decipher prostate genomic classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease.
Additionally, in June 2021, Thermo Fisher Scientific announced submissions open for the Oncomine Clinical Research Grant program to support clinical research projects in oncology. Due to this grant, the funding for high-quality molecular profiling studies focusing on the impact of immune-based treatments for cancer patients.
Market Segmentation
United States Prostate Cancer Testing Market can be segmented
Market Players
F. Hoffmann-La Roche Ltd (Foundation Medicine, Inc.), Siemens Healthcare GmbH, OPKO Health, Inc. (GenPath), Myriad Genetics Inc., NeoGenomics Laboratories, Danaher. (Beckman Coulter, Inc.), Agilent Technologies, Inc., Abcam plc., Bio-Techne. (ExoDx), H.U. Group Holdings, Inc. (Fujeribio) etc.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, Volume forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | Biomarker Type Application End User Region Company |
| Regional scope | Northeast Region, Midwest Region, South Region, West Region |
| Key companies profiled | F. Hoffmann-La Roche Ltd (Foundation Medicine, Inc.), Siemens Healthcare GmbH, OPKO Health, Inc. (GenPath), Myriad Genetics Inc., NeoGenomics Laboratories, Danaher. (Beckman Coulter, Inc.), Agilent Technologies, Inc., Abcam plc., Bio-Techne. (ExoDx), H.U. Group Holdings, Inc. (Fujeribio) |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy